Umeclidinium (BioDeep_00000837636)
代谢物信息卡片
Umeclidinium
化学式: C29H34NO2+ (428.25894040000003)
中文名称:
谱图信息:
最多检出来源 () 0%
分子结构信息
SMILES: C1C[N+]2(CCC1(CC2)C(C3=CC=CC=C3)(C4=CC=CC=C4)O)CCOCC5=CC=CC=C5
InChI: InChI=1S/C29H34NO2/c31-29(26-12-6-2-7-13-26,27-14-8-3-9-15-27)28-16-19-30(20-17-28,21-18-28)22-23-32-24-25-10-4-1-5-11-25/h1-15,31H,16-24H2/q+1
描述信息
C78272 - Agent Affecting Nervous System > C66880 - Anticholinergic Agent > C29704 - Antimuscarinic Agent
同义名列表
1 个代谢物同义名
数据库引用编号
7 个数据库交叉引用编号
- ChEBI: CHEBI:79041
- KEGGdrug: D10180
- PubChem: 11519070
- DrugBank: DB09076
- ChEMBL: CHEMBL1187833
- ChEMBL: CHEMBL523299
- CAS: 869185-19-3
分类词条
相关代谢途径
Reactome(0)
BioCyc(0)
PlantCyc(0)
代谢反应
0 个相关的代谢反应过程信息。
Reactome(0)
BioCyc(0)
WikiPathways(0)
Plant Reactome(0)
INOH(0)
PlantCyc(0)
COVID-19 Disease Map(0)
PathBank(0)
PharmGKB(0)
0 个相关的物种来源信息
在这里通过桑基图来展示出与当前的这个代谢物在我们的BioDeep知识库中具有相关联信息的其他代谢物。在这里进行关联的信息来源主要有：
- PubMed: 来源于PubMed文献库中的文献信息，我们通过自然语言数据挖掘得到的在同一篇文献中被同时提及的相关代谢物列表，这个列表按照代谢物同时出现的文献数量降序排序，取前10个代谢物作为相关研究中关联性很高的代谢物集合展示在桑基图中。
- NCBI Taxonomy: 通过文献数据挖掘，得到的代谢物物种来源信息关联。这个关联信息同样按照出现的次数降序排序，取前10个代谢物作为高关联度的代谢物集合展示在桑吉图上。
- Chemical Taxonomy: 在物质分类上处于同一个分类集合中的其他代谢物
- Chemical Reaction: 在化学反应过程中，存在为当前代谢物相关联的生化反应过程中的反应底物或者反应产物的关联代谢物信息。
点击图上的相关代谢物的名称，可以跳转到相关代谢物的信息页面。
文献列表
- Meng-Jer Hsieh, Ning-Hung Chen, Shih-Lung Cheng, Chi-Wei Tao, Yu-Feng Wei, Yao-Kuang Wu, Ming-Cheng Chan, Shih-Feng Liu, Wu-Huei Hsu, Tsung-Ming Yang, Ming-Shian Lin, Ching-Lung Liu, Ping-Hung Kuo, Ying-Huang Tsai. Comparing Clinical Outcomes of Tiotropium/Olodaterol, Umeclidinium/Vilanterol, and Indacaterol/Glycopyrronium Fixed-Dose Combination Therapy in Patients with Chronic Obstructive Pulmonary Disease in Taiwan: A Multicenter Cohort Study.
International journal of chronic obstructive pulmonary disease.
2022; 17(?):967-976. doi:
10.2147/copd.s353799. [PMID: 35510163] - Shuying Yang, Laurie A Lee, Neal Sule, Andrew Fowler, Guy Peachey. Population Pharmacokinetic Modeling of Fluticasone Furoate, Umeclidinium Bromide, and Vilanterol in Patients with Asthma, Using Data from a Phase IIIA Study (CAPTAIN).
Clinical pharmacokinetics.
2021 07; 60(7):887-896. doi:
10.1007/s40262-021-00988-1. [PMID: 33598874] - Rashmi Mehta, Colm Farrell, Siobhán Hayes, Ruby Birk, Malek Okour, David A Lipson. Population Pharmacokinetic Analysis of Fluticasone Furoate/Umeclidinium Bromide/Vilanterol in Patients with Chronic Obstructive Pulmonary Disease.
Clinical pharmacokinetics.
2020 01; 59(1):67-79. doi:
10.1007/s40262-019-00794-w. [PMID: 31321713] - Yan Li, Huafang Li, Yucheng Sheng, Xin Du, Yuhui Yao, Xian Luo, Peiming Ma. Pharmacokinetics of Single and Repeat Doses of Fluticasone Furoate/Umeclidinium/Vilanterol in Healthy Chinese Adults.
Clinical pharmacology in drug development.
2019 08; 8(6):721-733. doi:
10.1002/cpdd.626. [PMID: 30427594] - A Nasir, R Bissonnette, C Maari, J DuBois, T Pene Dumitrescu, J Haddad, Y Yamaguchi, M Dalessandro. A phase 2a randomized controlled study to evaluate the pharmacokinetic, safety, tolerability and clinical effect of topically applied Umeclidinium in subjects with primary axillary hyperhidrosis.
Journal of the European Academy of Dermatology and Venereology : JEADV.
2018 Jan; 32(1):145-151. doi:
10.1111/jdv.14651. [PMID: 29055158] - Ali M Yehia, Hany H Monir. An Umeclidinium membrane sensor; Two-step optimization strategy for improved responses.
Talanta.
2017 Sep; 172(?):61-67. doi:
10.1016/j.talanta.2017.05.019. [PMID: 28602304] - Shuying Yang, Laurie Lee, Steven Pascoe. Population Pharmacokinetics Modeling of Inhaled Umeclidinium for Adult Patients with Asthma.
European journal of drug metabolism and pharmacokinetics.
2017 Feb; 42(1):79-88. doi:
10.1007/s13318-016-0331-8. [PMID: 27026339] - T Pene Dumitrescu, L L Santos, S C Hughes, A I Pereira, G C Young, E Hussey, P Charlton, S Baptiste-Brown, J S Stuart, V Vincent, S P van Marle, V D Schmith. A Novel Method for Studying the Pharmacokinetics of [(14) C]Umeclidinium After Application to the Axilla or Palm of Healthy Male Subjects.
Clinical and translational science.
2016 08; 9(4):183-91. doi:
10.1111/cts.12406. [PMID: 27304394] - Rashmi Mehta, Michelle Green, Bela Patel, Jonathan Wagg. Concentration-QT analysis of the randomized, placebo- and moxifloxacin-controlled thorough QT study of umeclidinium monotherapy and umeclidinium/vilanterol combination in healthy subjects.
Journal of pharmacokinetics and pharmacodynamics.
2016 Apr; 43(2):153-64. doi:
10.1007/s10928-015-9461-x. [PMID: 26739997] - Shuying Yang, Laurie Lee, Stephen Mallett, Jonathan Ayer, Allen Wolstenholme, Steven Pascoe. A randomized, crossover study to investigate the pharmacokinetics and safety of inhaled fluticasone furoate and umeclidinium, administered separately and in combination via dry powder inhaler in healthy adult volunteers.
Advances in therapy.
2015 Feb; 32(2):157-71. doi:
10.1007/s12325-015-0184-6. [PMID: 25700806] - Rashmi Mehta, Kelly Hardes, Noushin Brealey, Lee Tombs, Andrew Preece, Dennis Kelleher. Effect of severe renal impairment on umeclidinium and umeclidinium/vilanterol pharmacokinetics and safety: a single-blind, nonrandomized study.
International journal of chronic obstructive pulmonary disease.
2015; 10(?):15-23. doi:
10.2147/copd.s68094. [PMID: 25565796] - Chaoying Hu, Jingying Jia, Kelly Dong, Linda Luo, Kai Wu, Rashmi Mehta, Jack Peng, Yan Ren, Annette Gross, Hui Yu. Pharmacokinetics and tolerability of inhaled umeclidinium and vilanterol alone and in combination in healthy Chinese subjects: a randomized, open-label, crossover trial.
PloS one.
2015; 10(3):e0121264. doi:
10.1371/journal.pone.0121264. [PMID: 25816315] - Jeff Sigler. Drug updates and approvals: 2014 in review.
The Nurse practitioner.
2014 Dec; 39(12):14-23; quiz 23. doi:
10.1097/01.npr.0000456393.83499.90. [PMID: 25350291] - Rashmi Mehta, Kelly Hardes, Dennis Kelleher, Andrew Preece, Lee Tombs, Noushin Brealey. Effects of moderate hepatic impairment on the pharmacokinetic properties and tolerability of umeclidinium and vilanterol in inhalational umeclidinium monotherapy and umeclidinium/vilanterol combination therapy: an open-label, nonrandomized study.
Clinical therapeutics.
2014 Jul; 36(7):1016-1027.e2. doi:
10.1016/j.clinthera.2014.05.002. [PMID: 24947493] - Navin Goyal, Misba Beerahee, Chris Kalberg, Alison Church, Sally Kilbride, Rashmi Mehta. Population pharmacokinetics of inhaled umeclidinium and vilanterol in patients with chronic obstructive pulmonary disease.
Clinical pharmacokinetics.
2014 Jul; 53(7):637-48. doi:
10.1007/s40262-014-0143-4. [PMID: 24756395] - Alison Church, Misba Beerahee, Jean Brooks, Rashmi Mehta, Palvi Shah. Dose response of umeclidinium administered once or twice daily in patients with COPD: a randomised cross-over study.
BMC pulmonary medicine.
2014 Jan; 14(?):2. doi:
10.1186/1471-2466-14-2. [PMID: 24393134] - Anthony Cahn, Rashmi Mehta, Andrew Preece, James Blowers, Alison Donald. Safety, tolerability and pharmacokinetics and pharmacodynamics of inhaled once-daily umeclidinium in healthy adults deficient in CYP2D6 activity: a double-blind, randomized clinical trial.
Clinical drug investigation.
2013 Sep; 33(9):653-64. doi:
10.1007/s40261-013-0109-6. [PMID: 23881566] - Anthony Cahn, Ruth Tal-Singer, Isabelle J Pouliquen, Rashmi Mehta, Andrew Preece, Kelly Hardes, Glenn Crater, Amanda Deans. Safety, tolerability, pharmacokinetics and pharmacodynamics of single and repeat inhaled doses of umeclidinium in healthy subjects: two randomized studies.
Clinical drug investigation.
2013 Jul; 33(7):477-88. doi:
10.1007/s40261-013-0088-7. [PMID: 23784369] - Ruth Tal-Singer, Anthony Cahn, Rashmi Mehta, Andrew Preece, Glenn Crater, Dennis Kelleher, Isabelle J Pouliquen. Initial assessment of single and repeat doses of inhaled umeclidinium in patients with chronic obstructive pulmonary disease: two randomised studies.
European journal of pharmacology.
2013 Feb; 701(1-3):40-8. doi:
10.1016/j.ejphar.2012.12.019. [PMID: 23276660] - James F Donohue, Antonio Anzueto, Jean Brooks, Rashmi Mehta, Christopher Kalberg, Glenn Crater. A randomized, double-blind dose-ranging study of the novel LAMA GSK573719 in patients with COPD.
Respiratory medicine.
2012 Jul; 106(7):970-9. doi:
10.1016/j.rmed.2012.03.012. [PMID: 22498110]